Detecting kidney injury early with exosome-based diagnostics

Researchers at Zhengzhou University have developed a powerful new way to detect kidney injury much earlier than current clinical methods allow. Kidney injury, whether caused by toxic drugs or chronic diseases like diabetes, often goes unnoticed until significant damage has already occurred.

Their approach focuses on urinary exosomes, tiny extracellular vesicles released by cells into urine that carry molecular cargo such as proteins and RNA. One such protein, neutrophil gelatinase-associated lipocalin (NGAL), is a known indicator of kidney stress. However, detecting NGAL in urine has been difficult because it is often present in very low amounts, especially during the early stages of damage.

To overcome this challenge, the researchers created a dual-signal amplification platform that combines DNase I-mediated biomarker cycling with metal-enhanced fluorescence (MEF). This technology dramatically increases detection sensitivity, making it possible to identify even trace levels of NGAL carried by urinary exosomes.

In laboratory tests, the platform successfully distinguished urine samples from patients with diabetic nephropathy and healthy donors, and in a rat model of cisplatin-induced acute kidney injury, it detected signs of damage just 12 hours after exposure—well before traditional biomarkers such as serum creatinine or blood urea nitrogen showed changes.

Beyond early diagnosis, this system could be used to monitor how patients respond to treatment, giving doctors a dynamic and precise tool for managing kidney disease. The study highlights the growing potential of exosome-based diagnostics in personalized medicine and disease monitoring.